Pharmaceuticals

Surge In Type 2 Diabetes Fueling The Growth Of The Due To Rising Obesity-induced Insulin Resistance Is Contributing To Changes In The Corifact Market

May 5, 2026May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Corifact Market Expected To Change From 2026 To 2030?

The expansion observed in the historic period was driven by the identification of fibrinogen deficiency, developments in trauma care, established protocols for surgical bleeding management, the authorization of plasma-derived therapies, and their subsequent incorporation by hospitals.

The expansion projected during the forecast period is driven by a surge in emergency operations, the growing demands of an aging population, the enlargement of trauma facilities, enhancements in coagulation diagnostic methods, and the escalating need for quick-acting hemostatic solutions.

Significant patterns emerging in the forecast period encompass an uptick in the utilization of fibrinogen concentrates, a primary emphasis on achieving rapid bleeding control, the proliferation of trauma and surgical treatment options, the implementation of hemostasis management within hospital settings, and a growing application in the management of liver diseases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Which Key Factors Are Driving The Corifact Market Growth?

The growing incidence of bleeding disorders is projected to boost the corifact market. These conditions hinder the blood’s ability to clot effectively, leading to excessive or prolonged bleeding. The increase in bleeding disorders stems from enhanced diagnosis, greater awareness, genetic testing advancements, lifestyle shifts, and the presence of underlying health issues. Corifact addresses bleeding disorders caused by factor XIII deficiency by substituting the absent clotting factor, thereby aiding in the formation of stable blood clots and diminishing excessive bleeding. For example, in December 2023, a report from the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), a UK-based entity, highlighted the burden of bleeding disorders in 2023/24, noting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, alongside 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the rising occurrence of bleeding disorders is a significant driver for the corifact market. A rising demand for biological products is set to propel the growth of the corifract market. Biological products are intricate pharmaceutical substances derived from living organisms, utilized for diagnosing, preventing, treating, and curing various diseases and medical conditions. This surge in demand for biological products is linked to heightened environmental concerns, increased consumer awareness, and the necessity for sustainable and effective alternatives to synthetic chemicals. Corifract contributes to biological products by enhancing their stability, bioavailability, and efficacy, ensuring optimal performance and extended shelf life through advanced formulation and delivery solutions. As an illustration, in August 2025, the Assistant Secretary for Planning and Evaluation, a US government department, stated that net revenue for biosimilars could range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger ones. Proposed regulatory adjustments, including universal interchangeability, a global comparator, and the removal of comparative efficacy studies, are estimated to reduce development costs and increase lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Hence, the escalating demand for biological products is driving the corifract market.

What Segment Categories Shape The Corifact Market Segment Landscape?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Who Are The Companies Operating Across The Corifact Market Value Chain?

Major companies operating in the corifact market are CSL Behring

Get The Full Corifact Market Report:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Which Region Is The Top Contributor To The Corifact Market By Share?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Corifact Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Browse Through More Reports Similar to the Global Corifact Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Consumer Credit Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-credit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795